Biora announces clinical device performance study results for NaviCap

Biora Therapeutics announced progress with its latest clinical device performance study, evaluating the device function and safety of its NaviCap targeted oral delivery platform. The NaviCap platform uses an ingestible device designed for targeted delivery of therapeutics to improve treatment of IBD. Once swallowed, Biora’s GItrac autolocation technology enables the device to autonomously identify targeted locations in the GI tract and release its payload.”We are continuing to see excellent device performance in human studies with the NaviCap platform, following similar results in three previous functional studies in both healthy volunteers and patients with active ulcerative colitis,” said Ariella Kelman, MD, Chief Medical Officer of Biora Therapeutics. “With more than 40 study participants receiving over 70 NaviCap devices to date, the combined results build confidence as we proceed toward an IND application in the third quarter of this year for our BT-600 program for treatment of ulcerative colitis,” continued Dr. Kelman.